This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NASDAQ Welcomes NephroGenex (NASDAQ:NRX) To The NASDAQ Stock Market

NEW YORK, Feb. 11, 2014 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of NephroGenex (Nasdaq:NRX), a drug development company focusing on kidney disease, commenced on The NASDAQ Stock Market on February 11, 2014.

NephroGenex ( is a pharmaceutical company focused on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. More than 20 million Americans have some form of chronic kidney disease, and over 400,000 in the U.S. have end stage renal disease requiring dialysis, making renal disease one of the costliest illnesses to treat. The Company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a chronic, therapeutic agent to slow the progression of diabetic nephropathy. Pyridorin™ has demonstrated preliminary evidence of efficacy in slowing the progression of diabetic nephropathy in three Phase 2 clinical studies. Pyridorin™ is one of only a few drug candidates in advanced clinical trials for diabetic kidney disease, and there are currently no adequate treatments for diabetic nephropathy.

"NephroGenex is a pioneer in the research and development of the treatment of kidney disease," said Nelson Griggs, Senior Vice President, NASDAQ OMX Corporate Client Group. "We are thrilled to welcome NephroGenex to The NASDAQ Stock Market and look forward to watching their continued growth and success in the future."

NephroGenex joins a variety of cutting-edge biotechnology companies that call NASDAQ OMX home. NASDAQ OMX has been the exchange of choice to 100 percent of biotech companies that have listed on the U.S. markets year-to-date in 2014.

Cautionary Note Regarding Forward-Looking Statements

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs